These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

231 related items for PubMed ID: 21863388

  • 1. [Treatment of metastatic melanoma with BRAF inhibitors].
    Hafner C.
    Hautarzt; 2011 Sep; 62(9):696-8. PubMed ID: 21863388
    [No Abstract] [Full Text] [Related]

  • 2. [BRAF mutation detection in metastatic melanoma].
    Dietel M, Enk A, Lehmann A, Bauer J, Garbe C, Kellner U, Kirchner T, Jung A, Kreipe H, Merkelbach-Bruse S, Büttner R, Rüschoff J, Schlake W, Schirmacher P, Penzel R, Stadler R.
    Pathologe; 2012 Jul; 33(4):352-6. PubMed ID: 22692278
    [No Abstract] [Full Text] [Related]

  • 3. BRAF(V600) mutation levels predict response to vemurafenib in metastatic melanoma.
    Lebbé C, How-Kit A, Battistella M, Sadoux A, Podgorniak MP, Sidina I, Pages C, Roux J, Porcher R, Tost J, Mourah S.
    Melanoma Res; 2014 Aug; 24(4):415-8. PubMed ID: 24933605
    [No Abstract] [Full Text] [Related]

  • 4. Cutaneous manifestations of vemurafenib therapy for metastatic melanoma.
    Owen JL, Lopez IE, Desai SR.
    J Drugs Dermatol; 2015 May; 14(5):509-10. PubMed ID: 25942671
    [Abstract] [Full Text] [Related]

  • 5. Vemurafenib in patients with BRAF(V600) mutated metastatic melanoma: an open-label, multicentre, safety study.
    Larkin J, Del Vecchio M, Ascierto PA, Krajsova I, Schachter J, Neyns B, Espinosa E, Garbe C, Sileni VC, Gogas H, Miller WH, Mandalà M, Hospers GA, Arance A, Queirolo P, Hauschild A, Brown MP, Mitchell L, Veronese L, Blank CU.
    Lancet Oncol; 2014 Apr; 15(4):436-44. PubMed ID: 24582505
    [Abstract] [Full Text] [Related]

  • 6. Abrupt development of Dupuytren's contractures with the BRAF inhibitor vemurafenib.
    Sibaud V, Chevreau C.
    Joint Bone Spine; 2014 Jul; 81(4):373-4. PubMed ID: 24468667
    [No Abstract] [Full Text] [Related]

  • 7. Community experience of vemurafenib for BRAF(V600) melanoma.
    Hersey P.
    Lancet Oncol; 2014 Apr; 15(4):369-70. PubMed ID: 24582506
    [No Abstract] [Full Text] [Related]

  • 8. BRAF inhibitors-induced panniculitis: a cutaneous side effect mimicking subcutaneous melanoma metastasis.
    Chaminade A, Conte H, Jouary T, Fauconneau A, Darrigade AS, Beylot-Barry M, Pham-Ledard A.
    J Eur Acad Dermatol Venereol; 2015 Feb; 29(2):392-393. PubMed ID: 24533578
    [No Abstract] [Full Text] [Related]

  • 9. Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial.
    Grob JJ, Amonkar MM, Karaszewska B, Schachter J, Dummer R, Mackiewicz A, Stroyakovskiy D, Drucis K, Grange F, Chiarion-Sileni V, Rutkowski P, Lichinitser M, Levchenko E, Wolter P, Hauschild A, Long GV, Nathan P, Ribas A, Flaherty K, Sun P, Legos JJ, McDowell DO, Mookerjee B, Schadendorf D, Robert C.
    Lancet Oncol; 2015 Oct; 16(13):1389-98. PubMed ID: 26433819
    [Abstract] [Full Text] [Related]

  • 10. Vemurafenib: in unresectable or metastatic melanoma.
    Keating GM.
    BioDrugs; 2012 Oct 01; 26(5):325-34. PubMed ID: 22946753
    [Abstract] [Full Text] [Related]

  • 11. Induction vemurafenib followed by consolidative radiation therapy for surgically incurable melanoma.
    Seeley AR, De Los Santos JF, Conry RM.
    Melanoma Res; 2015 Jun 01; 25(3):246-51. PubMed ID: 25746037
    [Abstract] [Full Text] [Related]

  • 12. Vemurafenib: a guide to its use in unresectable or metastatic melanoma.
    Keating GM, Lyseng-Williamson KA.
    Am J Clin Dermatol; 2013 Feb 01; 14(1):65-9. PubMed ID: 23329082
    [Abstract] [Full Text] [Related]

  • 13. Vemurafenib in melanoma.
    Shaw HM, Nathan PD.
    Expert Rev Anticancer Ther; 2013 May 01; 13(5):513-22. PubMed ID: 23617343
    [Abstract] [Full Text] [Related]

  • 14. [New treatment options for metastatic melanoma].
    Tietze JK, Berking C.
    Dtsch Med Wochenschr; 2014 Jul 01; 139(28-29):1462-7. PubMed ID: 24983194
    [No Abstract] [Full Text] [Related]

  • 15. Rapidly metastasizing malignant melanoma characterized by a rare BRAF mutation not responding to vemurafenib.
    Starz H, Gutschi M, Welzel J, Haas C.
    J Dtsch Dermatol Ges; 2014 Feb 01; 12(2):151-4. PubMed ID: 24238398
    [No Abstract] [Full Text] [Related]

  • 16. BRAF-Targeted Therapy to Treat Superior Vena Cava Syndrome in a Patient With Metastatic Cancer.
    Mesko SM, Rosenthal KJ, Boasberg PD, Hamid O.
    J Clin Oncol; 2015 Sep 01; 33(25):e101-3. PubMed ID: 24711550
    [No Abstract] [Full Text] [Related]

  • 17. Is a single BRAF wild-type test sufficient to exclude melanoma patients from vemurafenib therapy?
    Saint-Jean M, Quéreux G, Nguyen JM, Peuvrel L, Brocard A, Vallée A, Knol AC, Khammari A, Denis MG, Dréno B.
    J Invest Dermatol; 2014 May 01; 134(5):1468-1470. PubMed ID: 24025553
    [No Abstract] [Full Text] [Related]

  • 18. RASopathic alopecia: hair changes associated with vemurafenib therapy.
    Piraccini BM, Patrizi A, Fanti PA, Starace M, Bruni F, Melotti B, Misciali C, Dika E.
    J Am Acad Dermatol; 2015 Apr 01; 72(4):738-41. PubMed ID: 25773419
    [No Abstract] [Full Text] [Related]

  • 19. Vemurafenib in patients with BRAF V600E mutation-positive advanced melanoma.
    Ravnan MC, Matalka MS.
    Clin Ther; 2012 Jul 01; 34(7):1474-86. PubMed ID: 22742884
    [Abstract] [Full Text] [Related]

  • 20. Erythema nodosum-like panniculitis in patients with melanoma treated with vemurafenib.
    Sinha R, Edmonds K, Newton-Bishop J, Gore M, Larkin J, Fearfield L.
    J Clin Oncol; 2013 Jul 01; 31(19):e320-1. PubMed ID: 23715570
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.